NICLOU, Simone P. ; NORLUX Neuro-Oncology Laboratory, Department of Oncology, Luxembourg Institute of Health, Luxembourg, Luxembourg Department of Biomedicine, University of Bergen, Bergen, Norway
GOLEBIEWSKA, Anna ; NORLUX Neuro-Oncology Laboratory, Department of Oncology, Luxembourg Institute of Health, Luxembourg, Luxembourg
External co-authors :
yes
Language :
English
Title :
Turning strength into weakness: protein degradation and autophagy as therapeutic targets in glioblastoma?
Wang X, Meul T, Meiners S. Exploring the proteasome system: a novel concept of proteasome inhibition and regulation. Pharmacol Ther. 2020;211:107526.
Yang J, Nie J, Ma X, et al. Targeting PI3K in cancer: mechanisms and advances in clinical trials. Mol Cancer. 2019;18:26.
Thibaudeau TA, Smith DM. A practical review of proteasome pharmacology. Pharmacol Rev. 2019;71:170-197.
Benitez JA, Finlay D, Castanza A, et al. PTEN deficiency leads to proteasome addiction, a novel vulnerability in glioblastoma. Neuro Oncol. 2021;23:1072-1086.
Roth P, Mason WP, Richardson PG, Weller M. Proteasome inhibition for the treatment of glioblastoma. Expert Opin Investig Drugs. 2020;29:1133-1141.
Johansson P, Krona C, Kundu S, et al. A patient-derived cell atlas informs precision targeting of glioblastoma. Cell Rep. 2020;32:107897.
Abdul Rahim SA, Dirkse A, Oudin A, et al. Regulation of hypoxia-induced autophagy in glioblastoma involves ATG9A. Br J Cancer. 2017;117:813-825.
